Using extended-release naltrexone to prevent opioid overdose in people using stimulants and at risk for HIV
Taking Our Shot: Extended-Release Naltrexone as Opioid Overdose Pre-Exposure Prophylaxis (PrEP) in People Using Stimulants Living With or At Risk of HIV
This study is looking at whether a long-lasting injection of naltrexone can help prevent opioid overdoses in people who use stimulants and are living with or at risk for HIV, comparing it to regular harm reduction methods to see which works better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10908084 on NIH RePORTER |
What this research studies
This research investigates the use of a long-acting injectable form of naltrexone as a preventive measure against opioid overdose in individuals who use stimulants and are living with or at risk for HIV. The study will compare the effectiveness of this medication against a standard harm reduction approach in a randomized controlled trial. Participants will be monitored for their experiences and outcomes, and biomarkers will be used to assess substance use over time. The goal is to understand how this intervention can help reduce overdose deaths in this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who use stimulants and are living with or at risk for HIV.
Not a fit: Patients who do not use stimulants or are not at risk for HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of opioid overdose among individuals using stimulants and improve health outcomes for those living with or at risk for HIV.
How similar studies have performed: While the concept of opioid overdose pre-exposure prophylaxis is novel, similar approaches have shown promise in other populations, suggesting potential for success.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Appa, Ayesha a — University of California, San Francisco
- Study coordinator: Appa, Ayesha a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.